Related Experiment Video
Updated: May 16, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Abrupt evolution of Philadelphia chromosome-positive acute myeloid leukemia in myelodysplastic syndrome
Akiko Fukunaga1, Hiroto Sakoda, Yoshihiro Iwamoto
1Kitano Hospital The Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Abstract:
Myelodysplastic syndrome (MDS) is a clonal disorder arising from an alteration in multipotent stem cells, which lose the ability of normal proliferation and differentiation. Disease progression occurs in approximately 30% MDS cases. Specific chromosomal alterations seem responsible for each step in the evolution of acute myeloid leukemia (AML). Multiple genetic aberrations occur during the clonal evolution of MDS; however, few studies report the presence of the Philadelphia (Ph) chromosome. We report a rare case of Ph-positive AML, which evolved during the course of low-risk MDS. The patient, a 76-year-old man with mild leukocytopenia, was diagnosed with MDS, refractory neutropenia (RN). After 1.5 yr, his peripheral blood and bone marrow were suddenly occupied by immature basophils and myeloblasts, indicating the onset of AML. A bone marrow smear showed multilineage dysplasia, consistent with MDS evolution. Chromosomal analysis showed an additional t(9;22)(q34;q11) translocation. Because progression occurred concurrently with emergence of the Ph chromosome, we diagnosed this case as Ph-positive AML with basophilia arising from the clonal evolution of MDS. The patient was initially treated with nilotinib. A hematological response was soon achieved with disappearance of the Ph chromosome in the bone marrow. Emergence of Ph-positive AML in the course of low-risk MDS has rarely been reported. We report this case as a rare clinical course of MDS.
Insights
This study details a rare case of Philadelphia chromosome-positive acute myeloid leukemia evolving from low-risk myelodysplastic syndrome. Treatment with nilotinib achieved a hematological response and eliminated the Philadelphia chromosome.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Myelodysplastic syndrome (MDS) is a clonal stem cell disorder with a ~30% progression rate to acute myeloid leukemia (AML).
- Clonal evolution in MDS involves genetic aberrations, but the Philadelphia chromosome (Ph) is rarely reported.
- Philadelphia chromosome-positive AML is a distinct subtype, typically not arising from MDS.
Observation:
- A 76-year-old man with MDS and refractory neutropenia developed AML after 1.5 years.
- Peripheral blood and bone marrow showed immature basophils and myeloblasts, with multilineage dysplasia.
- Cytogenetic analysis revealed the Philadelphia chromosome translocation, t(9;22)(q34;q11).
Findings:
- The case presented as Philadelphia chromosome-positive AML with basophilia, evolving from low-risk MDS.
- The patient achieved a hematological response and Ph chromosome clearance with nilotinib treatment.
- This represents a rare clinical course of MDS progression.
Implications:
- Highlights the importance of cytogenetic analysis in MDS progression, even in low-risk cases.
- Suggests that Philadelphia chromosome-positive AML can arise from MDS clonal evolution.
- Nilotinib shows efficacy in treating Ph-positive AML emerging from MDS.

